Technical Analysis for IKT - Inhibikase Therapeutics, Inc.

Grade Last Price % Change Price Change
D 2.16 -6.09% -0.14
IKT closed down 6.09 percent on Thursday, March 28, 2024, on 60 percent of normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
Earnings due: Mar 29
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
Doji - Bearish? Reversal 0.00%
Doji - Bullish? Reversal 0.00%
Outside Day Range Expansion 0.00%
Gapped Down Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.09%
NR7 Range Contraction -6.09%
Narrow Range Bar Range Contraction -6.09%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 4 hours ago
Fell Below 10 DMA about 4 hours ago
Down 1 ATR about 5 hours ago
20 DMA Resistance about 6 hours ago
Fell Below 20 DMA about 6 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Inhibikase Therapeutics, Inc. Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Parkinson's Disease Neurological Disorders Dementia Psychiatric Diagnosis Stage Pharmaceutical Treatment Of Parkinson's Disease Aging Associated Diseases Neurodegenerative Disorders Pyridines Lewy Body Dementia Imatinib Multiple System Atrophy

Is IKT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.35
52 Week Low 0.79
Average Volume 163,578
200-Day Moving Average 1.95
50-Day Moving Average 2.37
20-Day Moving Average 2.23
10-Day Moving Average 2.15
Average True Range 0.22
RSI (14) 46.52
ADX 14.74
+DI 19.04
-DI 22.09
Chandelier Exit (Long, 3 ATRs) 1.83
Chandelier Exit (Short, 3 ATRs) 2.46
Upper Bollinger Bands 2.52
Lower Bollinger Band 1.95
Percent B (%b) 0.37
BandWidth 25.55
MACD Line -0.02
MACD Signal Line -0.03
MACD Histogram 0.0063
Fundamentals Value
Market Cap 13.36 Million
Num Shares 6.19 Million
EPS -3.99
Price-to-Earnings (P/E) Ratio -0.54
Price-to-Sales 49.63
Price-to-Book 1.13
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.71
Resistance 3 (R3) 2.74 2.59 2.62
Resistance 2 (R2) 2.59 2.45 2.58 2.59
Resistance 1 (R1) 2.38 2.37 2.30 2.34 2.56
Pivot Point 2.23 2.23 2.19 2.21 2.23
Support 1 (S1) 2.01 2.09 1.94 1.98 1.76
Support 2 (S2) 1.86 2.00 1.85 1.73
Support 3 (S3) 1.65 1.86 1.70
Support 4 (S4) 1.61